Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function

被引:99
作者
Watson, Ian R.
Blanch, Alvaro
Lin, Dan C. C.
Ohh, Michael
Irwin, Meredith S.
机构
[1] Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada
[3] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada
[4] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada
关键词
D O I
10.1074/jbc.M603654200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in p73 are rare in cancer. Emerging evidence suggests that the relative expression of various p73 isoforms may contribute to tumorigenesis. Alternative promoters and N-terminal splicing result in the transcription and processing of either full-length (TA) or N-terminally truncated (Delta N) p73 isoforms. TAp73 possesses pro-apoptotic functions, while Delta Np73 has anti-apoptotic properties via functional inhibition of TAp73 and p53. Here, we report that TAp73, but not Delta Np73, is covalently modified by NEDD8 under physiologic conditions in an Mdm2-dependent manner. Co-expression of NEDP1, a cysteine protease that specifically cleaves NEDD8 conjugates, was shown to deneddylate TAp73. In addition, blockage of the endogenous NEDD8 pathway increased TAp73-mediated transactivation of p53- and p73-responsive promoter-driven reporter activity, and in conjunction, neddylated TAp73 species were found preferentially in the cytoplasm. These results suggest that Mdm2 attenuates TAp73 transactivation function, at least in part, by promoting NEDD8-dependent TAp73 cytoplasmic localization and provide the first evidence of a covalent post-translational modification exclusively targeting the TA isoforms of p73.
引用
收藏
页码:34096 / 34103
页数:8
相关论文
共 54 条
  • [1] Agami R, 1999, NATURE, V399, P809
  • [2] Mdm2 binds p73α without targeting degradation
    Bálint, E
    Bates, S
    Vousden, KH
    [J]. ONCOGENE, 1999, 18 (27) : 3923 - 3929
  • [3] p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
    Bergamaschi, D
    Gasco, M
    Hiller, L
    Sullivan, A
    Syed, N
    Trigiante, G
    Yulug, I
    Merlano, M
    Numico, G
    Comino, A
    Attard, M
    Reelfs, O
    Gusterson, B
    Bell, AK
    Heath, V
    Tavassoli, M
    Farrell, PJ
    Smith, P
    Lu, X
    Crook, T
    [J]. CANCER CELL, 2003, 3 (04) : 387 - 402
  • [4] Ubiquitin-dependent degradation of p73 is inhibited by PML
    Bernassola, F
    Salomoni, P
    Oberst, A
    Di Como, CJ
    Pagano, M
    Melino, G
    Pandolfi, PP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (11) : 1545 - 1557
  • [5] Molecular characterization of the hdm2-p53 interaction
    Bottger, A
    Bottger, V
    GarciaEcheverria, C
    Chene, P
    Hochkeppel, HK
    Sampson, W
    Ang, K
    Howard, SF
    Picksley, SM
    Lane, DP
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1997, 269 (05) : 744 - 756
  • [6] Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients
    Casciano, I
    Mazzocco, K
    Boni, L
    Pagnan, G
    Banelli, B
    Allemanni, G
    Ponzoni, M
    Tonini, GP
    Romani, M
    [J]. CELL DEATH AND DIFFERENTIATION, 2002, 9 (03) : 246 - 251
  • [7] Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer.: Evidence for their role as epigenetic p53 inhibitors in vivo
    Concin, N
    Becker, K
    Slade, N
    Erster, S
    Mueller-Holzner, E
    Ulmer, H
    Daxenbichler, G
    Zeimet, A
    Zeillinger, R
    Marth, C
    Moll, UM
    [J]. CANCER RESEARCH, 2004, 64 (07) : 2449 - 2460
  • [8] Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer:: Evidence for a crucial p53-p73 cross-talk in vivo
    Concin, N
    Hofstetter, G
    Berger, A
    Gehmacher, A
    Reimer, D
    Watrowski, R
    Tong, D
    Schuster, E
    Hefler, L
    Heim, K
    Mueller-Holzner, E
    Marth, C
    Moll, UM
    Zeimet, AG
    Zeillinger, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (23) : 8372 - 8383
  • [9] CONSTANZO A, 2002, MOL CELL, V9, P175
  • [10] Two new p73 splice variants, γ and δ, with different transcriptional activity
    De Laurenzi, V
    Costanzo, A
    Barcaroli, D
    Terrinoni, A
    Falco, M
    Annicchiarico-Petruzzeli, M
    Levrero, M
    Melino, G
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) : 1763 - 1768